


## IRAK4-IN-18

Cat. No.:	HY-150732
Molecular Formula:	C <sub>24</sub> H <sub>25</sub> FN <sub>6</sub> O <sub>3</sub>
Molecular Weight:	464.49
Target:	IRAK
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC <sub>50</sub> value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	IRAK4 15 nM (IC <sub>50</sub> )									
<b>In Vitro</b>	IRAK4-IN-18 (compound 33) has inhibitory activity against LPS-induced IL23 in THP and DC with IC <sub>50</sub> s of 0.25 and 0.14 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
<b>In Vivo</b>	<p>IRAK4-IN-18 (5, 10 and 20 mg/kg; twice daily for 21 days) exhibits good efficacy in a mouse model for the inhibition of IL-6 production induced by IL-1β, and completely stops arthritis development in arthritis rats at 30 mg/kg<sup>[1]</sup>.</p> <p>IRAK4-IN-18 (1 mg/kg for IV, 5 mg/kg for PO, single dosage) exhibits a favorable pharmacokinetics profile with a clearance of 53 mL/min/kg and oral bioavailability of 38%<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Collagen-induced arthritis (CIA) rat models<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5, 10 and 20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>twice daily for 21 days</td> </tr> <tr> <td>Result:</td> <td>Completely stopped arthritis development based on hind paw clinical scores at 30 mg/kg dose, twice daily, and effectively decreased disease progression with 97% inhibition at 20 mg/kg dose, 56% inhibition at 10 mg/kg dose and 30% inhibition at 5 mg/kg dose.</td> </tr> </table>		Animal Model:	Collagen-induced arthritis (CIA) rat models <sup>[1]</sup>	Dosage:	5, 10 and 20 mg/kg	Administration:	twice daily for 21 days	Result:	Completely stopped arthritis development based on hind paw clinical scores at 30 mg/kg dose, twice daily, and effectively decreased disease progression with 97% inhibition at 20 mg/kg dose, 56% inhibition at 10 mg/kg dose and 30% inhibition at 5 mg/kg dose.
Animal Model:	Collagen-induced arthritis (CIA) rat models <sup>[1]</sup>									
Dosage:	5, 10 and 20 mg/kg									
Administration:	twice daily for 21 days									
Result:	Completely stopped arthritis development based on hind paw clinical scores at 30 mg/kg dose, twice daily, and effectively decreased disease progression with 97% inhibition at 20 mg/kg dose, 56% inhibition at 10 mg/kg dose and 30% inhibition at 5 mg/kg dose.									

### REFERENCES

[1]. Chen Y, et al. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors. Bioorg Med Chem Lett. 2022 Jul 18:128900.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA